Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06600789 · ClinicalTrials.gov registry record · Phase 1
A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
A Phase 1 study of Solid Malignancies, sponsored by Carrick Therapeutics Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 6
- Study locations
NCT06600789 is a Phase 1 study of Solid Malignancies that is actively recruiting participants, run by Carrick Therapeutics Limited. The registered enrollment target is 50 participants, below the 88-participant average among 3 other Solid Malignancies trials with a reported enrollment target (43% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT06600789, a Phase 1 study of Solid Malignancies, is actively recruiting participants, sponsored by Carrick Therapeutics Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 6
- Study locations
Study Summary
This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies.
Conditions Studied
Interventions
- DRUG CT7439 Capsules (0.5 mg, 1mg, 3mg)
Study Locations (6)
Other
- Research site 05 - Manchester
- Research site 04 - Oxford
- Research site 06 - Sutton
Texas
- Research site 03 - Dallas
- Research site 01 - San Antonio
Virginia
- Research site 02 - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-08-16 |
| Est. Completion | 2026-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06600789
The ClinicalTrials.gov registry entry for NCT06600789 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 3 other Solid Malignancies trials with a reported enrollment target (43% lower). The listed sponsor is Carrick Therapeutics Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Malignancies appearing as the primary indexed condition, and to 1 intervention - of which CT7439 Capsules (0.5 mg, 1mg, 3mg) is the first listed.
NCT06600789 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Other, Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT06600789 about?
NCT06600789 is a clinical study titled "A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies". This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies.
What is the current status of trial NCT06600789?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2024-08-16. Estimated completion is 2026-05-22.
What conditions does trial NCT06600789 study?
This clinical trial studies the following conditions: Solid Malignancies.
What interventions are being tested in trial NCT06600789?
The interventions under investigation include: CT7439 Capsules (0.5 mg, 1mg, 3mg) (DRUG).
Who is sponsoring clinical trial NCT06600789?
This trial is sponsored by Carrick Therapeutics Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06600789 being conducted?
This trial has 6 study locations across Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
RECRUITING · Phase 1
-
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.